





ORIGINAL RESEARCH

Relationship Between a Plant-Based Dietary Portfolio and Risk of Cardiovascular Disease: Findings From the Women's Health Initiative Prospective Cohort Study

Andrea J. Glenn, MSc, RD;* Kenneth Lo , PhD;* David J. A. Jenkins, MD, PhD; Beatrice A. Boucher, MHSc; Anthony J. Hanley, PhD; Cyril W. C. Kendall, PhD; JoAnn E. Manson , MD, DrPH; Mara Z. Vitolins, DrPH, RDN; Linda G. Snetselaar, PhD; Simin Liu , MD, PhD; John L. Sievenpiper , MD, PhD

BACKGROUND: The plant-based Dietary Portfolio combines established cholesterol-lowering foods (plant protein, nuts, viscous fiber, and phytosterols), plus monounsaturated fat, and has been shown to improve low-density lipoprotein cholesterol and other cardiovascular disease (CVD) risk factors. No studies have evaluated the relation of the Dietary Portfolio with incident CVD events.

METHODS AND RESULTS: We followed 123 330 postmenopausal women initially free of CVD in the Women's Health Initiative from 1993 through 2017. We used Cox proportional-hazard models to estimate adjusted hazard ratios (HRs) and 95% CI of the association of adherence to a Portfolio Diet score with CVD outcomes. Primary outcomes were total CVD, coronary heart disease, and stroke. Secondary outcomes were heart failure and atrial fibrillation. Over a mean follow-up of 15.3 years, 13 365 total CVD, 5640 coronary heart disease, 4440 strokes, 1907 heart failure, and 929 atrial fibrillation events occurred. After multiple adjustments, adherence to the Portfolio Diet score was associated with lower risk of total CVD (HR, 0.89; 95% CI, 0.83–0.94), coronary heart disease (HR, 0.86; 95% CI, 0.78–0.95), and heart failure (HR, 0.83; 95% CI, 0.71–0.99), comparing the highest to lowest quartile of adherence. There was no association with stroke (HR, 0.97; 95% CI, 0.87–1.08) or atrial fibrillation (HR, 1.10; 95% CI, 0.87–1.38). These results remained statistically significant after several sensitivity analyses.

CONCLUSIONS: In this prospective cohort of postmenopausal women in the United States, higher adherence to the Portfolio Diet was associated with a reduction in incident cardiovascular and coronary events, as well as heart failure. These findings warrant further investigation in other populations.

Key Words: cardiovascular disease ■ dietary patterns ■ dietary portfolio ■ plant-based ■ prospective cohort study

The Dietary Portfolio, or Portfolio Diet, is a plant-based dietary pattern that was developed in the early 2000s to lower low-density lipoprotein cholesterol (LDL-C).^{1–6} The underlying diet is low in saturated fat and cholesterol (National Cholesterol

Education Program Step II diet⁷), with the addition of a “portfolio” of 4 cholesterol-lowering foods and nutrients: nuts, plant protein (soy and pulses), viscous fiber (oats, barley, psyllium, eggplant, okra, apples, oranges, and berries), and phytosterols (originally provided as

Correspondence to: Simin Liu, MD, PhD, Department of Epidemiology, Brown University, 121 South Main St, Providence, RI 02903; and John L. Sievenpiper, MD, PhD, St. Michael's Hospital, #6138-61 Queen Street East, Toronto, Ontario M5C 2T2, Canada. E-mails: simin_liu@brown.edu (S.L.), john.sievenpiper@utoronto.ca (J.L.S.)

*A. J. Glenn and K. Lo contributed equally.

This article was sent to Holli A. DeVon, PhD, Guest Editor, for review by expert referees, editorial decision, and final disposition.

Supplementary Material for this article is available at <https://www.ahajournals.org/doi/suppl/10.1161/JAHA.121.021515>

For Sources of Funding and Disclosures, see page 11.

© 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

JAHA is available at: www.ahajournals.org/journal/jaha

CLINICAL PERSPECTIVE

What Is New?

- Higher adherence to the Portfolio Diet was associated with a 11%, 14%, and 17% lower risk of total cardiovascular disease, coronary heart disease, and heart failure, respectively, but no association was seen with stroke or atrial fibrillation.
- This study shows that the beneficial effects of the Portfolio Diet on cardiovascular risk factors from the clinical trials may translate into lower hard clinical cardiovascular disease events.

What Are the Clinical Implications?

- Given the increased interest in plant-based foods and diets around the world, and growing concerns related to ethical and environmental implications of diet, the Portfolio Diet warrants attention from healthcare professionals as another therapeutic dietary approach for cardiovascular disease risk reduction.

Nonstandard Abbreviations and Acronyms

FFQ	food frequency questionnaire
MUFAs	monounsaturated fatty acids
OS	observational study
WHI	Women's Health Initiative

enriched margarine). An extension of the diet includes adding monounsaturated fats (MUFAs; such as olive/canola oil or avocado).⁶ Early findings from a metabolically controlled randomized trial showed that the LDL-C lowering effect of the Portfolio Diet was similar to the control diet taken with 20mg lovastatin (−28.6% versus −30.9%).³ Recently, a systematic review and meta-analysis of metabolically controlled and ad libitum trials showed that the Portfolio Diet significantly lowered LDL-C by 17% (27% in the intended combination with an National Cholesterol Education Program Step II diet). It also lowered other cardiovascular disease (CVD) risk factors, including the alternate blood lipid targets of non-high-density lipoprotein cholesterol by 14% and ApoB (apolipoprotein B) by 15%, and CRP (C-reactive protein) by 32%.⁸ These benefits have been recognized by CVD and diabetes mellitus clinical practice guidelines internationally, including those of the Canadian Cardiovascular Society,⁹ Diabetes Canada,¹⁰ European Atherosclerosis Society,¹¹ and Heart UK.¹²

Currently, it is not known if these beneficial effects of the diet translate into lower risk of clinical CVD events. The individual components of the Portfolio

Diet have been found to be associated with lower incidence of CVD events in prospective cohorts,^{13–17} and 2 components of the diet (nuts and extra virgin olive oil) were shown to reduce major vascular events in the landmark PREDIMED (Prevención con Dieta Mediterránea) trial compared to a low saturated fat¹⁸ however, the additive/combined effects of the Portfolio Diet components have not been assessed with incident CVD. Although conducting a long-term randomized trial with CVD as the primary outcome would be preferable, this type of trial is not yet feasible. Analyses of established observational studies may be helpful in assessing the long-term effectiveness of the Portfolio Diet. We have therefore developed a scoring system to measure adherence to the Portfolio Diet for use in these study designs. Here, for the first time, we have evaluated the association of a Portfolio Diet score with CVD outcomes in the WHI (Women's Health Initiative).

METHODS

Study Population and Design

The design and methods of the WHI have been published elsewhere.^{19–21} Briefly, between 1993 and 1998, postmenopausal women aged 50 to 79 years were recruited into clinical trials or an observational study (OS) (n=161 808). Recruitment and baseline data collection have been previously reported.²⁰ This analysis includes follow-up through February 28, 2017. We excluded participants who had a history of CVD at baseline (n=32 594), and missing information regarding diet and lifestyle covariates or implausible caloric intake (<600 kcal or >5000 kcal/day) (n=5884). The final analysis included 123 330 women (Figure 1). The baseline characteristics of participants included or excluded due to missing data from the analysis are shown in Table S1. Written informed consent was obtained from all WHI participants and procedures were approved by institutional review boards at all participating institutions. The WHI data are accessible to qualified researchers trained in human subject confidentiality protocols and requests to access the data set may be sent to the WHI Publications and Presentations Committee.

Dietary Assessment

The exposure was diet as measured by a Portfolio Diet score. The foods and nutrients composing this score were self-reported using the food frequency questionnaire (FFQ) developed and validated for the WHI^{22,23} at enrollment and again at year 3 for the OS participants. No further diet assessments were available for the WHI participants. We used a cumulative average score for those who completed the FFQ at baseline and year 3 (Data S1).




Figure 1. Flow chart for study sample, WHI (Women's Health Initiative) cohort, 1993 to 2017.

Food items on the WHI FFQ that are characteristic of the Portfolio Diet were categorized into 6 components (plant protein, nuts, viscous fiber, phytosterols, MUFAs, and saturated fat/cholesterol sources). Intake was assessed as servings/day of targeted foods in all components except phytosterols, which used all FFQ food items to derive total daily intake (mg/day). For the 6 components, each was scored from 1 (unhealthy) to 5 (healthiest) according to participant's quintile of intake resulting in a score range between 6 and 30, with higher scores indicating higher adherence to the Portfolio Diet. Additional information on the Portfolio Diet score development is provided in Data S1 and Table S2.

Ascertainment of CVD Outcomes

Our primary outcomes included total CVD, coronary heart disease (CHD; defined as clinical myocardial infarction, definite silent myocardial infarction, or a death due to definite CHD or possible CHD), and stroke incidence and death as these CVDs are causally related to high LDL-C and the Portfolio Diet has an established cholesterol-lowering effect.⁸ Total CVD was a composite of nonfatal myocardial infarction, CHD death, stroke, coronary revascularization and incident heart failure (HF).²⁴ Our secondary, or exploratory, outcomes included HF and atrial fibrillation (AF). The outcomes

were ascertained in the WHI through self-reported medical questionnaires completed by participants every 6 to 12 months, depending on study assignment. Medical records and death certificates for all outcomes were reviewed by central physician adjudicators or trained local adjudicators.²⁵

Covariates

Covariates that were included in our models were based on information on the participants' lifestyle and risk factors for CVD assessed at baseline, including age, region in the United States, race/ethnicity, alcohol intake, physical activity, caloric intake, sodium intake, hysterectomy history, body mass index (BMI), hormone therapy use, personal history of hypertension and high cholesterol, family history of CVD and diabetes mellitus, diabetes mellitus or cancer diagnoses, smoking status, education, marital status, and clinical trial/study arm. Detailed descriptions of the validity and reproducibility of baseline measurements have been previously published.²¹

Statistical Analysis

Baseline characteristics were described by quartile of the Portfolio Diet score using means with SDs for continuous variables and frequencies with

percentages for categorical variables. To compare baseline characteristics, χ^2 tests were used for categorical variables and analysis of variance for continuous variables.

Participants were categorized into quartiles of the Portfolio Diet score, with the lowest quartile serving as the reference group, as per our prespecified analysis plans. Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% CIs for the association between the Portfolio Diet score quartiles and CVD outcomes. Two multivariable models were used. Covariates commonly examined in studies of dietary pattern scores and CVD risk were included based on our a priori analysis plan. Model 1 was adjusted for age (continuous), region (Northeast, South, Midwest, West), smoking (never, past, current), and study arm (hormone replacement therapy arm, dietary modification arm, calcium and vitamin D arm). Model 2 was adjusted for model 1+race/ethnicity (White, Black, Hispanic, Asian/Pacific Islander, Other [American Indian, Alaskan Native, other]), education (college or above, below college), marital status (presently married/other), hysterectomy history (yes/no), body mass index (continuous), physical activity (continuous), alcohol intake (>7 drinks/week, <7 drinks/week), energy intake (continuous), cancer status (yes/no), hypertension status (yes/no), diabetes mellitus status (yes/no), sodium intake (continuous), family history of CVD (yes/no), family history of diabetes mellitus (yes/no), postmenopausal hormone use (never, past, current), and cholesterol-lowering medication use (yes/no). For all covariates, 5% or less of values were missing. When we checked the proportional hazard model assumptions using Schoenfeld residuals method, no violations of the assumption were found.

Tests for linear trend were conducted by assigning the median value to each quartile. Our main analysis (per our protocol) included all WHI participants (clinical trials+OS). We also conducted several sensitivity analyses to test the robustness of our main findings. First, we conducted analyses by restricting the data to the OS participants only as the clinical trials participants have received an intervention and may be different from the OS participants. We also then (1) restricted analyses to the baseline diet only, (2) excluded participants from the dietary modification trial (a low fat diet intervention), as their diet may have changed overtime, (3) excluded CVD events within the first 3 years of follow-up to address possible reverse causation, (4) excluded those with diabetes mellitus at baseline due to their higher CVD risk, and (5) completed multiple imputation for missing covariate data (using

the multivariate imputation by chained equations method).²⁶ We also conducted post hoc sensitivity analyses where we created another Portfolio Diet score based on the recommendations from the Portfolio Diet randomized clinical trials (further details included in Table S3). We then also applied subgroup analyses according to several potential interactive factors (age, body mass index, family history of CVD, race/ethnicity, smoking status, and cholesterol-lowering medication) and conducted interaction tests via multiplicative interaction terms using model 2 to assess if the *P* for interactions were significant. Additional analyses we conducted included evaluating associations between the 6 individual components of the Portfolio Diet and risk of the CVD outcomes. Statistical tests were 2-sided and *P*<0.05 was considered statistically significant. The statistical analyses were conducted with Stata statistical software (Stata Statistical Software: Release 15., Stata Corp., College Station, TX). Further information on the methods can be found in Data S1.

RESULTS

Lifestyle Characteristics of the Participants

Baseline characteristics by quartiles of the Portfolio Diet score are shown in Table 1. Women with higher scores tended to be older, have a lower body mass index, engage in more physical activity, have a higher education, be less likely to smoke, as well as several other differences. All of these known risk factors at baseline were adjusted for in our analyses. Mean intake of the Portfolio Diet score components is shown in Table 2. The included participants were different from the excluded participants (eg, Black or Hispanic, 10 118 [8.2%] and 4875 [4.0%] versus 1061 [19.0%] and 657 [10.2%], respectively; and above college education, 83 887 [68.5%] versus 3086 [55.9%]) (Table S1).

Portfolio Diet Score and CVD Outcomes

During an average of 15.3 years of follow-up, we documented 13 365 incident CVD cases, including 5640 CHD cases, 4400 stroke cases, 1907 HF cases, and 929 AF cases. After adjusting for potential confounders, we observed that women in the top quartile (Q4) of the Portfolio Diet score, compared to those in the bottom quartile (Q1), had an HR of 0.89 (95% CI, 0.83–0.94; *P*<0.001 for trend) for risk of total CVD, 0.86 (95% CI, 0.78–0.95; *P*<0.001 for trend) for risk of CHD, and 0.97 (95% CI, 0.87–1.08; *P*=0.50 for trend) for stroke (Table 3 and Figure 2). For our exploratory outcomes, we observed that women in the top quartile compared

Table 1. Baseline Characteristics of 123 330 Participants in the WHI According to Quartiles of the Portfolio Diet Score

Mean (SD)/No. (%)	Q1 (6–14)	Q2 (14.5–17)	Q3 (17.5–20)	Q4 (20.5–30)	P Value
Number of participants	32 403	33 713	30 755	26 459	
Time-to-event/censored in years	14.9 (5.79)	15.4 (5.67)	15.5 (5.61)	15.6 (5.58)	<0.001
Age, y	62.2 (7.05)	62.6 (7.07)	62.9 (7.17)	63.1 (7.27)	<0.001
Body mass index, kg/m ²	28.7 (6.08)	28.0 (5.81)	27.6 (5.69)	26.7 (5.54)	<0.001
Recreational physical activity (MET-h/wk)	9.60 (12.01)	11.99 (13.2)	13.64 (14.15)	16.77 (15.63)	<0.001
Dietary energy, kcal/d	1368 (522)	1577 (603)	1755 (640)	1933 (665)	<0.001
Region in the United States					
Northeast	9635 (29.7)	8066 (23.9)	6331 (20.6)	4459 (16.9)	<0.001
South	8261 (25.5)	8804 (26.1)	7951 (25.9)	6360 (24.0)	
Midwest	7794 (24.1)	8018 (23.8)	6706 (21.8)	4588 (17.3)	
West	6713 (20.7)	8825 (26.2)	9767 (31.8)	11 052 (41.8)	
Race/ethnicity					
White	26 517 (82.0)	28 582 (85.0)	26 019 (84.8)	22 166 (84.0)	<0.001
Black	3869 (12.0)	2757 (8.2)	2106 (6.9)	1368 (5.3)	
Hispanic	1023 (3.2)	1229 (3.7)	1337 (4.4)	1286 (4.9)	
Asian/Pacific Islander	582 (1.8)	714 (2.1)	881 (2.9)	1213 (4.6)	
Alcoholic drinks					
>7 drinks/wk	3789 (11.7)	4217 (12.6)	3782 (12.3)	3314 (12.6)	0.003
Sodium intake, mg/d	2204 (888)	2607 (1044)	2953 (1142)	3329 (1240)	<0.001
Hormone therapy use					
Never	12 055 (38.3)	10 853 (33.2)	9592 (32.3)	7550 (29.5)	<0.001
Past	7404 (23.5)	7270 (22.2)	6334 (21.3)	5586 (21.8)	
Current	12 021 (38.2)	14 602 (44.6)	13 830 (46.5)	12 500 (48.8)	
Hysterectomy ever	13 230 (40.8)	13 607 (40.4)	12 228 (39.8)	10 107 (38.2)	<0.001
Treated high cholesterol	3284 (10.8)	3730 (11.8)	3450 (12.0)	3002 (12.0)	<0.001
History of hypertension	10 396 (32.3)	10 208 (30.5)	8981 (29.4)	7044 (26.8)	<0.001
History of cancer	2707 (8.4)	2829 (8.5)	2680 (8.8)	2296 (8.8)	0.223
Family history diabetes mellitus	10 583 (32.8)	10 685 (31.8)	9626 (31.4)	7770 (29.4)	<0.001
Family history of cardiovascular disease	20 816 (64.2)	21 898 (64.9)	20 248 (65.8)	17 167 (64.9)	<0.001
Self-reported diabetes mellitus	1578 (4.9)	1603 (4.8)	1442 (4.7)	1118 (4.2)	0.001
Smoking status					
Never	15 706 (48.5)	17 049 (50.6)	16 253 (52.9)	14 323 (54.1)	<0.001
Past	13 281 (50.0)	142 401 (42.2)	12 891 (41.9)	11 166 (42.2)	
Current	3416 (10.5)	2424 (7.20)	1611 (5.2)	970 (3.7)	
Education: college or above	19 165 (59.6)	22 256 (66.5)	21 918 (71.8)	20 548 (78.2)	<0.001
Marital status: present relationship	19 785 (61.3)	21 640 (64.5)	20 032 (65.4)	16 946 (64.3)	<0.001
Hormone replacement therapy arm					
Not randomized	25 436 (78.6)	27 904 (82.8)	25 845 (84.0)	22 468 (84.9)	<0.001
E-alone	1368 (4.2)	1055 (3.1)	924 (3.0)	640 (2.4)	
E-alone control	1442 (4.5)	1076 (3.2)	826 (2.7)	754 (2.9)	
E+P intervention	2083 (6.4)	1930 (5.7)	1653 (5.4)	1306 (4.9)	
E+P control	2074 (6.4)	1748 (5.2)	1507 (4.9)	1291 (4.9)	
Dietary modification arm					
Not randomized	20 972 (64.7)	22 964 (68.1)	21 349 (69.4)	18 958 (71.7)	<0.001
Intervention	4472 (13.8)	4268 (12.7)	3867 (12.6)	2981 (11.3)	
Control	6959 (21.5)	6481 (19.2)	5539 (18.0)	4520 (17.1)	

(Continued)

Table 1. Continued

Mean (SD)/No. (%)	Q1 (6–14)	Q2 (14.5–17)	Q3 (17.5–20)	Q4 (20.5–30)	P Value
Calcium and vitamin D arm					
Not randomized	23 646 (73.0)	25 738 (76.3)	23 738 (77.2)	20 778 (78.5)	<0.001
Intervention	4398 (13.6)	3982 (11.8)	3529 (11.5)	2865 (10.8)	
Control	4359 (13.5)	3993 (11.8)	3477 (11.3)	2816 (10.6)	

E+P indicates estrogen plus progestin; E-alone, estrogen-alone; Q, quartile; and WHI, Women’s Health Initiative

to those in the bottom quartile had an HR of 0.83 (95% CI, 0.71–0.99; *P*=0.01 for trend) for HF and 1.10 (95% CI, 0.87–1.38; *P*=0.73 for trend) for AF (Table 3 and Figure 2). Absolute incidence rates per 100 000 person-years among quartiles of adherence are shown in Tables 3 and 4.

Sensitivity Analyses

The associations between the Portfolio Diet score and CVD outcomes remained similar in all sensitivity analyses (in the OS participants only [Table 4], and baseline diet only, excluding participants from the dietary modification trial, excluding CVD events within the first 3 years of follow-up, excluding those with diabetes mellitus, and completing multiple imputation for missing covariate data [Table S4]). For HF, however, after excluding events diagnosed in the first 3 years,

the association was slightly attenuated and no longer significant (Table S4). The association between the Portfolio Diet score based on the randomized clinical trials recommendations and CVD outcomes were attenuated and no longer significant for some outcomes; however, patterns were similar to our original a priori analysis (Table S3).

Subgroup Analyses

The results remained largely consistent in each of the subgroup analyses, apart from effect modification by smoking status and CHD (Figures S1 through S5).

Individual Component Analyses

When we individually assessed the 6 components of the Portfolio Diet score with the CVD outcomes,

Table 2. Scoring Criteria for the Portfolio Diet Score From Targeted Foods in Each Component and Mean* Daily Intake† for Each Quintile

Component	Main Targeted Foods From WHI FFQ‡	Scoring Criteria				
		Q1 (1 Point), servings/d	Q2 (2 Points), servings/d	Q3 (3 Points), servings/d	Q4 (4 Points), servings/d	Q5 (5 Points), servings/d
Plant protein	Soy beverage; green peas; refried beans; all other beans; tofu and textured vegetable products; bean soups	0.05	0.13	0.21	0.34	0.77
Viscous fiber	Oranges, grapefruit and tangerines; apples and pears; strawberries; okra; oats	0.14	0.38	0.64	0.98	1.78
Nuts	Peanut butter, peanuts, other nuts and seeds	0.00	0.04	0.10	0.23	0.62
Phytosterols	Estimated from all plant foods	133 mg	191 mg	236 mg	288 mg	404 mg
MUFAs	Olive or canola oil; avocado and guacamole	0.00	...§	0.01	0.03	0.25
Saturated fat/cholesterol	High fat dairy; eggs; chicken/turkey with skin; red and processed meats; organ meats; gravy; butter	4.19	2.04	1.34	0.86	0.38

FFQ indicates food frequency questionnaire; MUFAs, monounsaturated fatty acids; and Q, quintile.

*Mean of baseline and year 3 FFQ, when possible.

†All components reported as servings/day except for phytosterols (mg/day).

‡Full list of FFQ food items in Table S1 in the Supplementary Appendix.

§Two points not given to any participants based on consumption on MUFAs (low in entire population).

||Higher quintiles represent higher intake; however, high intake and high quintiles of saturated fat/cholesterol received lower scores.

Table 3. Prospective Association of the Portfolio Diet Score With Risk of Cardiovascular Disease Outcomes Among 123 330 Participants in the Women's Health Initiative (CT+OS) (1993–2017)

	Cases/Total	Person-Years	Incidence Rate (Per 100 000 Person-Years)	Model 1* (n=123 330)		Model 2† (n=104, 894)	
				HR (95% CI)	P Value	HR (95% CI)	P Value
Total CVD							
Q1 (6–14)	3872/32 403	459 280	834	1.00 [reference]		1.00 [reference]	
Q2 (14.5–17)	3758/33 713	493 872	760	0.92 (0.88–0.96)	<0.001	0.97 (0.92–1.02)	0.259
Q3 (17.5–20)	3189/30 755	456 016	699	0.84 (0.80–0.88)	<0.001	0.91 (0.86–0.96)	0.001
Q4 (20.5–30)	2549/26 459	396 421	643	0.77 (0.74–0.82)	<0.001	0.89 (0.83–0.94)	<0.001
P trend							<0.001
CHD							
Q1 (6–14)	1697/32 403	474 873	357	1.00 [reference]		1.00 [reference]	
Q2 (14.5–17)	1528/33 713	510 244	299	0.85 (0.80–0.91)	<0.001	0.92 (0.85–0.99)	0.029
Q3 (17.5–20)	1328/30 755	469 623	282	0.80 (0.74–0.86)	<0.001	0.85 (0.78–0.93)	<0.001
Q4 (20.5–30)	1087/26 459	406 937	267	0.75 (0.69–0.81)	<0.001	0.86 (0.78–0.95)	0.002
P trend							<0.001
Stroke							
Q1 (6–14)	1192/32 403	476 881	250	1.00 [reference]		1.00 [reference]	
Q2 (14.5–17)	1256/33 713	511 321	246	0.99 (0.91–1.07)	0.811	1.03 (0.95–1.13)	0.449
Q3 (17.5–20)	1061/30 755	471 010	225	0.89 (0.82–0.97)	0.008	0.97 (0.88–1.07)	0.545
Q4 (20.5–30)	892/26 459	407 674	219	0.86 (0.79–0.94)	0.001	0.97 (0.87–1.08)	0.598
P trend							0.500
Heart failure							
Q1 (6–14)	567/32 403	479 309	118	1.00 [reference]		1.00 [reference]	
Q2 (14.5–17)	566/33 713	513 986	110	0.96 (0.85–1.08)	0.493	0.97 (0.85–1.11)	0.704
Q3 (17.5–20)	450/30 755	473 311	95	0.83 (0.73–0.94)	0.003	0.86 (0.75–0.99)	0.046
Q4 (20.5–30)	326/26 459	410 002	80	0.70 (0.61–0.80)	<0.001	0.83 (0.71–0.99)	0.034
P trend							0.010
Atrial fibrillation							
Q1 (6–14)	266/32 403	482 208	55	1.00 [reference]		1.00 [reference]	
Q2 (14.5–17)	257/33 713	517 112	50	1.04 (0.88–1.24)	0.635	1.06 (0.87–1.28)	0.547
Q3 (17.5–20)	212/30 755	475 797	45	0.95 (0.79–1.14)	0.564	0.94 (0.76–1.16)	0.553
Q4 (20.5–30)	194/26 459	411 730	47	1.05 (0.87–1.27)	0.573	1.10 (0.87–1.38)	0.418
P trend							0.725

Quartile 1 represents the least adherent to the Portfolio Diet, whereas quartile 4 represents the most adherence to the Portfolio Diet. Associations between Portfolio Diet and outcomes were determined by Cox proportional hazard models. Under/over energy reporters and those with baseline CVD were excluded from the analysis. Total CVD is a composite of incidence and death of CHD, stroke, heart failure, and coronary revascularization (coronary artery bypass grafting or percutaneous transluminal coronary angioplasty). CHD indicates coronary heart disease; CT, clinical trial; CVD, cardiovascular disease; HR, hazard ratio; OS, observational study; and Q, quartile.

*Model 1 adjusted for age (continuous), region (Northeast, South, Midwest, West), smoking (never, past, current), and study arm (hormone replacement therapy arm, dietary modification arm, calcium and vitamin D arm).

†Model 2 adjusted for model 1+race/ethnicity (White, Black, Hispanic, Asian/Pacific Islander, Other [American Indian, Alaskan Native, other]), education (college or above, below college), marital status (presently married/other), hysterectomy history (yes/no), body mass index (continuous), physical activity (continuous), alcohol intake (>7 drinks/week, <7 drinks/week), energy intake (continuous), cancer status (yes/no), hypertension status (yes/no), diabetes mellitus status (yes/no), sodium intake (continuous), family history of CVD (yes/no), family history of diabetes mellitus (yes/no), hormone therapy use (never, past, current), cholesterol-lowering medication use (yes/no).

higher intakes of nuts, phytosterols, and MUFAs and lower intake of saturated fat sources had inverse associations with total CVD. Phytosterols and low saturated fat sources had inverse associations with CHD and phytosterols had inverse associations with stroke. Nuts also had an inverse association with HF (Table S5).

DISCUSSION

In this large prospective cohort study of US postmenopausal women, a higher Portfolio Diet score was associated with a 11% and 14% lower risk of total CVD and CHD, respectively, but no association was seen with stroke. These findings remained consistent across all




Figure 2. Summary of findings of incident cardiovascular disease, coronary heart disease, stroke, heart failure, and atrial fibrillation comparing low to high adherence to the Portfolio Diet. Hazard ratios (HRs) and for comparing participants in Q1 (low adherence [reference category]) to Q4 (high adherence) of the Portfolio Diet with CVD outcomes in the Women’s Health Initiative (Clinical Trials+Observational Study). Multivariate-adjusted models were adjusted for the following: age, region, smoking, clinical trial study arm, ethnicity, education, marital status, hysterectomy history, body mass index, physical activity, alcohol intake, energy intake, cancer status, hypertension status, diabetes mellitus status, sodium intake, family history of CVD, family history of diabetes mellitus, hormone therapy use, and cholesterol-lowering medication use. P trend was determined by assigning a median value to each quartile. Horizontal lines represent 95% CIs. CHD indicates coronary heart disease; and CVD, cardiovascular disease.

sensitivity analyses, including when we excluded the WHI clinical trial participants, highlighting the robustness of our results. There was also a strong linear trend for greater adherence to the Portfolio Diet with total CVD and CHD. For our secondary analysis, there was an association of a 17% lower risk of HF with a higher Portfolio Diet score, but no association was seen with AF. The true benefits of the Portfolio Diet on CVD risk reduction, however, are likely underestimated in the current study.

Interpretation of Results and Implications

These findings are consistent with the Portfolio Diet trial evidence assessing effects on intermediate risk factors for CVD. The Portfolio Diet has been shown to result in clinically meaningful reductions in the lipid targets

for CVD prevention (LDL-C, non-high-density lipoprotein cholesterol, ApoB), as well as CRP, with smaller reductions in blood pressure.⁸ In particular, LDL-C, the primary risk factor that the Portfolio Diet was designed to reduce, is considered causal in the pathogenesis of atherosclerotic CVD based on evidence from cardiovascular outcomes trials involving 3 different classes of drugs (statins, ezetimibe, and PCSK9 inhibitors), Mendelian randomization studies and prospective cohorts.²⁷ Our strongest finding of a 14% inverse association with CHD is consistent with these lines of evidence and closely reflects the predicted 10-year CHD risk reduction of 13% estimated in our systematic review and meta-analysis of the Portfolio Diet trials.⁸ The 0.73 mmol/L reduction in LDL-C that corresponds to this 13% reduction in the Portfolio Diet trials

Table 4. Prospective Association of the Portfolio Diet Score With Risk of Cardiovascular Disease Outcomes Among 70 506 Participants in the Observational Study of the Women’s Health Initiative (1993–2017)

	Cases/Total	Person-Years	Incidence Rate (Per 100 000 Person-Years)	Model 1* (n=69 196)		Model 2† (n=60 923)	
				HR (95% CI)	P Value	HR (95% CI)	P Value
Total CVD							
Q1 (6–14)	1721/16 472	222 515	773	1.00 [reference]		1.00 [reference]	
Q2 (14.5–17)	1910/19 350	274 964	694	0.89 (0.83–0.95)	<0.001	0.94 (0.88–1.01)	0.091
Q3 (17.5–20)	1654/18 297	264 916	624	0.79 (0.74–0.84)	<0.001	0.86 (0.78–0.93)	<0.001
Q4 (20.5–30)	1345/16 387	241 091	558	0.71 (0.66–0.76)	<0.001	0.85 (0.78–0.93)	<0.001
P trend							<0.001
CHD							
Q1 (6–14)	745/16 472	229 456	325	1.00 [reference]		1.00 [reference]	
Q2 (14.5–17)	752/19 350	283 605	265	0.79 (0.72–0.88)	<0.001	0.87 (0.78–0.97)	0.012
Q3 (17.5–20)	681/18 297	271 936	250	0.74 (0.66–0.82)	<0.001	0.81 (0.72–0.91)	<0.001
Q4 (20.5–30)	577/16 387	246 743	234	0.69 (0.61–0.77)	<0.001	0.82 (0.71–0.93)	0.003
P trend							0.002
Stroke							
Q1 (6–14)	496/16 472	230 524	215	1.00 [reference]		1.00 [reference]	
Q2 (14.5–17)	631/19 350	283 869	222	0.99 (0.88–1.20)	0.922	1.05 (0.92–1.19)	0.448
Q3 (17.5–20)	533/18 297	272 608	196	0.86 (0.76–0.97)	0.015	0.93 (0.81–1.07)	0.310
Q4 (20.5–30)	446/16 387	247 169	180	0.78 (0.69–0.89)	<0.001	0.92 (0.78–1.08)	0.320
P trend							0.224
Heart failure							
Q1 (6–14)	292/16 472	231 297	126	1.00 [reference]		1.00 [reference]	
Q2 (14.5–17)	300/19 350	285 357	105	0.88 (0.74–1.03)	0.114	0.88 (0.73–1.05)	0.156
Q3 (17.5–20)	233/18 297	273 961	85	0.71 (0.59–0.85)	<0.001	0.75 (0.62–0.92)	0.005
Q4 (20.5–30)	193/16 387	248 275	78	0.67 (0.56–0.81)	<0.001	0.80 (0.64–1.00)	0.053
P trend							0.009
Atrial fibrillation							
Q1 (6–14)	20/16 472	232 957	9	1.00 [reference]		1.00 [reference]	
Q2 (14.5–17)	24/19 350	287 170	8	0.89 (0.49–1.62)	0.704	1.33 (0.67–2.56)	0.401
Q3 (17.5–20)	14/18 297	275 243	5	0.57 (0.29–1.13)	0.108	0.87 (0.40–1.94)	0.764
Q4 (20.5–30)	18/16 387	249 464	7	0.80 (0.41–1.54)	0.510	1.33 (0.60–2.94)	0.484
P trend							0.749

Quartile 1 represents the least adherent to the Portfolio Diet, whereas quartile 4 represents the most adherence to the Portfolio Diet. Associations between Portfolio Diet and outcomes were determined by Cox proportional hazard models. Under/over energy reporters and those with baseline CVD were excluded from the analysis. Total CVD is a composite of incidence and death of CHD, stroke, heart failure, and coronary revascularization (coronary artery bypass grafting or percutaneous transluminal coronary angioplasty). CHD indicates coronary heart disease; CVD, cardiovascular disease; HR, hazard ratio; and Q, quartile.

*Model 1 adjusted for age (continuous), region (Northeast, South, Midwest, West), and smoking (never, past, current).

†Model 2 adjusted for model 1+ethnicity (White, Black, Hispanic, Asian/Pacific Islander, Other [American Indian, Alaskan Native, other]), education (college or above, below college), marital status (presently married/other), hysterectomy history (yes/no), body mass index (continuous), physical activity (continuous), alcohol intake (>7 drinks/week, <7 drinks/week), energy intake (continuous), cancer status (yes/no), hypertension status (yes/no), diabetes mellitus status (yes/no), sodium intake (continuous), family history of CVD (yes/no), family history of diabetes mellitus (yes/no), hormone therapy use (never, past, current), cholesterol-lowering medication use (yes/no).

is predicted by the regression line for the observed risk reduction per mmol/L of LDL-C seen within the updated analyses of the CTT (Cholesterol Treatment Trialists) collaboration.²⁸

We are unaware of other studies examining the association of a Portfolio Diet with CVD events. The individual components of the Portfolio Diet, however, have been associated with lower rates of CVD events

in prospective cohorts. Systematic reviews and meta-analyses have shown that consumption of legumes,¹³ dietary fiber including viscous fiber sources,¹⁴ nuts,¹⁵ and MUFAs¹⁶ are associated with reductions in CVD events, and consumption of foods high in saturated fat (such as red and processed meats) are associated with an increased risk of CVD.¹⁷ The inverse association of increasing phytosterol intake from natural sources with

CVD risk in our study, however, was not shown in an earlier study.²⁹

The Portfolio Diet also shows similar results to other recognized dietary patterns for CVD prevention, such as the Dietary Approaches to Stop Hypertension, vegetarian, Nordic, and Mediterranean diets, which share important overlap in core foods (nuts, legumes, whole grains, fruit/vegetable sources, and/or mono-unsaturated fat).^{18,30–33} Systematic reviews and meta-analyses of prospective cohort studies and large individual cohort studies have shown the Dietary Approaches to Stop Hypertension diet is associated with a 20% (95% CI, 0.76–0.85 HRs) reduction in CVD and a 21% reduction (0.71–0.88) in CHD incidence,³⁰ whereas Nordic and vegetarian diets are associated with 29% (0.65–0.78) and 22% (0.69–0.88) reductions in CVD and CHD mortality, respectively.^{31,33} Similarly, the PREDIMED trial, a large randomized cardiovascular outcomes trial of the effect of a Mediterranean diet supplemented with either extra virgin olive oil or nuts compared with a low-fat diet, found reductions in major vascular events of 31% (0.53–0.91) and 28% (0.54–0.95), respectively.¹⁸

Dietary patterns have also shown similar results specifically within the WHI. Higher adherence to the Healthy Eating Index 2010, Alternative Healthy Eating Index 2010, Alternate Mediterranean and Dietary Approaches to Stop Hypertension diets have been associated with 18% to 26% lower CVD mortality risk in the OS participants,³⁴ which falls within the 95% CIs (HR, 0.85; 95% CI, 0.78–0.93) of our findings for total CVD comparing lowest to highest adherence of the Portfolio Diet score in these participants. The 30% reduction in HF associated with higher adherence to the Alternative Healthy Eating Index²⁴ also falls within the 95% CIs (HR, 0.80; 95% CI, 0.64–0.99) of our findings for the Portfolio Diet in the OS participants.

Unlike some other dietary patterns, adherence to the Portfolio Diet was not associated with a reduction in stroke in our study. Both the Mediterranean and Dietary Approaches to Stop Hypertension diets have shown inverse associations with stroke.^{30,32} Although the Portfolio Diet resulted in a reduction in blood pressure in the randomized trials,⁸ this effect may not be strong enough to translate into an association with lower stroke risk, given that the reductions were small and hypertension is the most important risk factor for stroke.³⁵ The larger reductions in LDL-C and other lipid targets, as well as CRP, may be more relevant for the inverse associations seen with CHD and total CVD than with stroke. AF is also a major risk factor for stroke,³⁶ and we did not observe a significant association with lower AF risk in our study.

These findings highlight the plant-based Portfolio Diet as another dietary therapeutic approach for CVD prevention, alongside other dietary patterns

recommended for CVD prevention. As adherence is one of the most critical determinants for attaining the benefits of any diet, as recognized by cardiovascular clinical practice guidelines,⁹ the Portfolio Diet may best fit with the values and preferences of some patients and allow them to achieve the greatest adherence long term. The Portfolio Diet also has a small ecological footprint, emphasizing plant-based components with low environmental impact (eg, legumes, oats, barley, temperate fruit, etc).^{37,38} Given increasing public concerns regarding ethical and environmental impact of food,^{39,40} healthcare professionals will likely have more patients interested in this dietary pattern.

Strengths and Limitations

Strengths of our study include the prospective cohort design, large sample size, and long follow-up for incident CVD events. Nevertheless, this study does have limitations. First, our study included only 1 or 2 assessments of diet, and diet was self-reported. Second, the population included health-conscious postmenopausal women and therefore the results may not be generalizable to men or other populations; however, the Portfolio Diet trials were conducted in both men and postmenopausal women and benefits were seen in both sexes. Third, causation cannot be established because of the observational design, and residual confounding also cannot be ruled out. Lastly, consumption of many of the Portfolio Diet components remained low, particularly plant protein and MUFAs, even in the top quintiles. A few of the Portfolio Diet foods, such as some viscous fiber sources (eg, barley), were also not included on the FFQ. This finding was further highlighted in our post hoc sensitivity analysis where we created a Portfolio Diet score based on the recommendations of the Portfolio Diet trials. No participants in the WHI received the maximum amount of points possible, and maximum points suggested ≈50% adherence to the trial recommendations, with an average estimated adherence of ≈22%. These adherence estimations are, however, likely underestimated given the nature of FFQs and their inability to determine absolute intake of diets. Taken together, we expect that the associations are likely underestimated, and a stronger association with CVD events may be seen with greater consumption of the Portfolio Diet components. This low adherence reflects an important opportunity for individuals to achieve cardiovascular benefits of the Portfolio Diet. Typical dietary patterns in North America and Europe do not meet the targets for plant protein, viscous fiber, nuts, phytosterols, and MUFAs of the Portfolio Diet,^{41–46} and therefore public health initiatives that focus on the components of the diet may improve cardiovascular outcomes globally.

It will be of great interest to apply this Portfolio Diet score to other populations, particularly in those that consume greater amounts of the diet components, to assess if similar or stronger associations with incident CVD events are found.

CONCLUSIONS

Greater adherence to the plant-based Portfolio Diet score was significantly associated with lower risk of total CVD, CHD, and HF in postmenopausal women. These findings provide the strongest evidence to date on the long-term benefits of a Portfolio Diet in the primary prevention of CVD, although our Portfolio Diet score needs to be assessed in other cohorts/populations to confirm these findings. Evidence from randomized trials with clinical CVD events is also needed. In this regard, we await the results of the PortfolioEX trial (ClinicalTrials.gov Identifier: NCT02481466) of the effect of the Portfolio Diet plus exercise on a surrogate marker of atherosclerotic CVD risk (magnetic resonance imaging of atherosclerosis [plaque volume]). In the meantime, our results support the Portfolio Diet as another therapeutic dietary approach for managing CVD risk that fits with current guidelines emphasizing plant-based diets.

ARTICLE INFORMATION

Received March 10, 2021; accepted May 27, 2021.

Affiliations

Department of Nutritional Sciences, University of Toronto, Ontario, Canada (A.J.G., D.J.J., B.A.B., A.J.H., C.W.K., J.L.S.); Clinical Nutrition and Risk Factor Modification Center (A.J.G., D.J.J., C.W.K., J.L.S.); and Toronto 3D Knowledge Synthesis and Clinical Trials Unit (A.J.G., D.J.J., C.W.K., J.L.S.), St. Michael's Hospital, Toronto, Ontario, Canada; Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China (K.L.); Centre for Global Cardiometabolic Health, Brown University, Providence, RI (K.L., S.L.); Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada (D.J.J., J.L.S.); Division of Endocrinology and Metabolism, St. Michael's Hospital, Toronto, Ontario, Canada (D.J.J., J.L.S.); Dalla Lana School of Public Health and Department of Medicine, University of Toronto, Ontario, Canada (A.J.H.); Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada (A.J.H.); College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, Canada (C.W.K.); Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (J.E.M.); Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA (J.E.M.); Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (J.E.M.); Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC (M.Z.V.); Department of Epidemiology, University of Iowa College of Public Health, Iowa City, IA (L.G.S.); Division of Endocrinology, Department of Medicine, and Division of Cardiothoracic Surgery, Department of Surgery, The Warren Alpert School of Medicine and Rhode Island Hospital, Providence, RI (S.L.); and Department of Epidemiology, Brown University School of Public Health, Providence, RI (S.L.).

Acknowledgments

We thank all participants in the WHI clinical trials and cohort for their invaluable contribution. We also thank volunteer Chloe Kavcic and researchers Drs Isabelle Sioen and Joline Beulens (EPIC-NL) for their contributions to the phytosterol database developed for this study.

Author contributions: A.J.G., K.L., S.L., and J.L.S. had full access to the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. A.J.G., K.L., D.J.A.J., B.A.B., A.J.H., C.W.C.K., S.L., J.L.S. designed the study. A.J.G., K.L., and S.L. performed the statistical analyses. A.J.G. drafted the article. S.L. and J.L.S. supervised the project. All authors contributed to the data interpretation and revised each draft for important intellectual content. All authors read and approved the final article.

Sources of Funding

The Women's Health Initiative (WHI) was funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, and U.S. Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600002C, HHSN268201600003C, HHSN268201600004C, and R01DK125403 (SL). Glenn was supported by the Nora Martin Fellowship in Nutritional Sciences, the Banting & Best Diabetes Centre Tamarack Graduate Award in Diabetes Research, the Peterborough K.M. Hunter Charitable Foundation Graduate Award and an Ontario Graduate Scholarship. Sievenpiper was funded by a Diabetes Canada Clinician Scientist Award. Lo was supported by Start-up Fund for RAPs under the Strategic Hiring Scheme (Grant number: BD8H). Funders had no role in the study design, the collection, analysis and interpretation of data, the writing of the report, and the decision to submit the article for publication.

Disclosures

A.J.G. received funding from the Nora Martin Fellowship in Nutritional Sciences, Banting & Best Diabetes Centre Tamarack Graduate Award in Diabetes Research, the Peterborough K.M. Hunter Charitable Foundation Graduate Award, and the Ontario Graduate Scholarship. She has received consulting fees from Solo GI Nutrition and has received an honorarium from the Soy Nutrition Institute. D.J.A.J. has received research grants from Saskatchewan & Alberta Pulse Growers Associations, the Agricultural Bioproducts Innovation Program through the Pulse Research Network, the Advanced Foods and Material Network, Loblaw Companies Ltd., Unilever Canada and Netherlands, Barilla, the Almond Board of California, Agriculture and Agri-food Canada, Pulse Canada, Kellogg's Company, Canada, Quaker Oats, Canada, Procter & Gamble Technical Centre Ltd., Bayer Consumer Care, Springfield, NJ, Pepsi/Quaker, International Nut & Dried Fruit Council (INC), Soy Foods Association of North America, the Coca-Cola Company (investigator initiated, unrestricted grant), Solae, Haine Celestial, the Sanitarium Company, Orafit, the International Tree Nut Council Nutrition Research and Education Foundation, the Peanut Institute, Soy Nutrition Institute (SNI), the Canola and Flax Councils of Canada, the Calorie Control Council, the Canadian Institutes of Health Research (CIHR), the Canada Foundation for Innovation (CFI) and the Ontario Research Fund (ORF). He has received in-kind supplies for trials as a research support from the Almond board of California, Walnut Council of California, the Peanut Institute, Barilla, Unilever, Unico, Primo, Loblaw Companies, Quaker (Pepsico), Pristine Gourmet, Bunge Limited, Kellogg Canada, WhiteWave Foods. He has been on the speaker's panel, served on the scientific advisory board and/or received travel support and/or honoraria from 2020 China Glycemic Index (GI) International Conference, Atlantic Pain Conference, Academy of Life Long Learning, the Almond Board of California, Canadian Agriculture Policy Institute, Loblaw Companies Ltd, the Griffin Hospital (for the development of the NuVal scoring system), the Coca-Cola Company, Epicure, Danone, Diet Quality Photo Navigation (DQPN), Better Therapeutics (FareWell), Verywell, True Health Initiative (THI), Heali AI Corp, Institute of Food Technologists (IFT), Soy Nutrition Institute (SNI), Herbalife Nutrition Institute (HNI), Saskatchewan & Alberta Pulse Growers Associations, Sanitarium Company, Orafit, the International Tree Nut Council Nutrition Research and Education Foundation, the Peanut Institute, Herbalife International, Pacific Health Laboratories, Nutritional Fundamentals for Health (NFH), Barilla, Metagenics, Bayer Consumer Care, Unilever Canada and Netherlands, Solae, Kellogg, Quaker Oats, Procter & Gamble, Abbott Laboratories, Dean Foods, the California Strawberry Commission, Haine Celestial, PepsiCo, the Alpro Foundation, Pioneer Hi-Bred International, DuPont Nutrition and Health, Spherix Consulting and WhiteWave Foods, the Advanced Foods and Material Network, the Canola and Flax Councils of Canada, Agri-Culture and Agri-Food Canada, the Canadian Agri-Food Policy Institute, Pulse Canada, the Soy Foods Association of North America, the Nutrition Foundation of Italy (NFI), Nutra-Source Diagnostics, the McDougall Program, the Toronto Knowledge Translation Group (St. Michael's Hospital), the Canadian College of Naturopathic Medicine, The Hospital for Sick Children, the Canadian Nutrition Society (CNS), the American Society of Nutrition (ASN), Arizona

State University, Paolo Sorbini Foundation and the Institute of Nutrition, Metabolism and Diabetes. He received an honorarium from the United States Department of Agriculture to present the 2013 W.O. Atwater Memorial Lecture. He received the 2013 Award for Excellence in Research from the International Nut and Dried Fruit Council. He received funding and travel support from the Canadian Society of Endocrinology and Metabolism to produce mini cases for the Canadian Diabetes Association (CDA). He is a member of the International Carbohydrate Quality Consortium (ICQC). His wife, Alexandra L Jenkins, is a director and partner of INQUIS Clinical Research for the Food Industry, his 2 daughters, Wendy Jenkins and Amy Jenkins, have published a vegetarian book that promotes the use of the foods described here, *The Portfolio Diet for Cardiovascular Risk Reduction* (Academic Press/Elsevier 2020 ISBN:978-0-12-810510-8) and his sister, Caroline Brydson, received funding through a grant from the St. Michael's Hospital Foundation to develop a cookbook for one of his studies. A.J.H. received independent investigator-initiated research funding from Dairy Farmers of Canada. C.W.C.K. has received research support from the Advanced Foods and Materials Network, Agricultural Bioproducts Innovation Program through the Pulse Research Network, Agriculture and Agri-Food Canada, Almond Board of California, Barilla, Calorie Control Council, Canadian Institutes of Health Research, Canola Council of Canada, The International Tree Nut Council Nutrition Research & Education Foundation, Kellogg, Loblaw Companies Ltd., Pulse Canada, Saskatchewan Pulse Growers, and Unilever. He has received consultant fees from American Pistachio Growers; speaker fees from Tate & Lyle and The WhiteWave Foods Company; and travel funding from Sabra Dipping Company, Tate & Lyle, International Tree Nut Council Research & Education Foundation, California Walnut Commission, Sun-Maid, The Peanut Institute, General Mills, Oldways Foundation and International Nut and Dried Fruit Council Foundation. He is on the Clinical Practice Guidelines Expert Committee for Nutrition Therapy of the European Association for the Study of Diabetes. He is a member of the International Carbohydrate Quality Consortium, Secretary of the Diabetes and Nutrition Study Group of the European Association for the Study of Diabetes, and a director of the Toronto 3D Knowledge Synthesis and Clinical Trials foundation. J.L.S. has received research support from the Canadian Foundation for Innovation, Ontario Research Fund, Province of Ontario Ministry of Research and Innovation and Science, Canadian Institutes of Health Research (CIHR), Diabetes Canada, PSI Foundation, Banting and Best Diabetes Centre (BBDC), American Society for Nutrition (ASN), INC International Nut and Dried Fruit Council Foundation, National Dried Fruit Trade Association, National Honey Board (the U.S. Department of Agriculture [USDA] honey "Checkoff" program), International Life Sciences Institute (ILSI), Pulse Canada, Quaker, The United Soybean Board (the USDA soy "Checkoff" program), The Tate and Lyle Nutritional Research Fund at the University of Toronto, The Glycemic Control and Cardiovascular Disease in Type 2 Diabetes Fund at the University of Toronto (a fund established by the Alberta Pulse Growers), and The Nutrition Trialists Fund at the University of Toronto (a fund established by an inaugural donation from the Calorie Control Council). He has received in-kind food donations to support a randomized controlled trial from the Almond Board of California, California Walnut Commission, Peanut Institute, Barilla, Unilever/Upfield, Unico/Primo, Loblaw Companies, Quaker, Kellogg Canada, WhiteWave Foods/Danone, and Nutrartis. He has received travel support, speaker fees and/or honoraria from Diabetes Canada, Dairy Farmers of Canada, FoodMinds LLC, International Sweeteners Association, Nestlé, Pulse Canada, Canadian Society for Endocrinology and Metabolism (CSEM), GI Foundation, Abbott, General Mills, Biofortis, ASN, Northern Ontario School of Medicine, INC Nutrition Research & Education Foundation, European Food Safety Authority (EFSA), Comité Européen des Fabricants de Sucre (CEFS), Nutrition Communications, International Food Information Council (IFIC), Calorie Control Council, and Physicians Committee for Responsible Medicine. He has or has had ad hoc consulting arrangements with Perkins Coie LLP, Tate & Lyle, Wirtschaftliche Vereinigung Zucker e.V., Danone, and Inquis Clinical Research. He is a member of the European Fruit Juice Association Scientific Expert Panel and Soy Nutrition Institute (SNI) Scientific Advisory Committee. He is on the Clinical Practice Guidelines Expert Committees of Diabetes Canada, European Association for the study of Diabetes (EASD), Canadian Cardiovascular Society (CCS), and Obesity Canada/Canadian Association of Bariatric Physicians and Surgeons. He serves or has served as an unpaid scientific advisor for the Food, Nutrition, and Safety Program (FNSP) and the Technical Committee on Carbohydrates of ILSI North America. He is a member of the International Carbohydrate Quality Consortium (ICQC), Executive Board Member of the Diabetes and Nutrition Study Group (DNSG) of the EASD, and Director of the Toronto 3D Knowledge Synthesis and Clinical

Trials foundation. His wife is an employee of AB InBev. There are no other relationships or activities that could appear to have influenced the submitted work.

Supplementary Material

Data S1
Appendix S1
Tables S1–S5
Figures S1–S5
References 47–57

REFERENCES

- Jenkins DJA, Kendall CWC, Faulkner D, Vidgen E, Trautwein EA, Parker TL, Marchie A, Koumbriidis G, Lapsley KG, Josse RG, et al. A dietary portfolio approach to cholesterol reduction: combined effects of plant sterols, vegetable proteins, and viscous fibers in hypercholesterolemia. *Metabolism*. 2002;51:1596–1604. DOI: 10.1053/meta.2002.35578.
- Jenkins DJA, Kendall CWC, Marchie A, Faulkner D, Vidgen E, Lapsley KG, Trautwein EA, Parker TL, Josse RG, Leiter LA, et al. The effect of combining plant sterols, soy protein, viscous fibers, and almonds in treating hypercholesterolemia. *Metabolism*. 2003;52:1478–1483. DOI: 10.1016/S0026-0495(03)00260-9.
- Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, de Souza R, Emam A, Parker TL, Vidgen E, Lapsley KG, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and c-reactive protein. *JAMA*. 2003;290:502–510. DOI: 10.1001/jama.290.4.502.
- Jenkins DJA, Kendall CWC, Faulkner DA, Nguyen T, Kemp T, Marchie A, Wong JMW, de Souza R, Emam A, Vidgen E, et al. Assessment of the longer-term effects of a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. *Am J Clin Nutr*. 2006;83:582–591. DOI: 10.1093/ajcn.83.3.582.
- Jenkins DJA, Jones PJH, Lamarche B, Kendall CWC, Faulkner D, Cermakova L, Giguere I, Ramprasad V, de Souza R, Ireland C, et al. Effect of a dietary portfolio of cholesterol-lowering foods given at 2 levels of intensity of dietary advice on serum lipids in hyperlipidemia: a randomized controlled trial. *JAMA*. 2011;306:831–839. DOI: 10.1001/jama.2011.1202.
- Jenkins DJ, Chiavaroli L, Wong JM, Kendall C, Lewis GF, Vidgen E, Connelly PW, Leiter LA, Josse RG, Lamarche B. Adding monounsaturated fatty acids to a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. *CMAJ*. 2010;182:1961–1967. DOI: 10.1503/cmaj.092128.
- Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). *JAMA*. 2001;285:2486–2497. DOI: 10.1001/jama.285.19.2486.
- Chiavaroli L, Nishi SK, Khan TA, Braunstein CR, Glenn AJ, Mejia SB, Rahelić D, Kahleová H, Salas-Salvadó J, Jenkins DJA, et al. Portfolio dietary pattern and cardiovascular disease: a systematic review and meta-analysis of controlled trials. *Prog Cardiovasc Dis*. 2018;61:43–53. DOI: 10.1016/j.pcad.2018.05.004.
- Anderson TJ, Grégoire J, Pearson GJ, Barry AR, Couture P, Dawes M, Francis GA, Genest J Jr, Grover S, Gupta M, et al. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. *Can J Cardiol*. 2016;32:1263–1282. DOI: 10.1016/j.cjca.2016.07.510.
- Diabetes Canada Clinical Practice Guidelines Expert C, Sievenpiper JL, Chan CB, Dworatzek PD, Freeze C, Williams SL. Nutrition therapy. *Can J Diabetes*. 2018;42(suppl 1):S64–S79. DOI: 10.1016/j.cjcd.2017.10.009.
- Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, et al.; European Atherosclerosis Society Consensus P. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. *Eur Heart J*. 2015;36:1012–1022. DOI: 10.1093/eurheartj/ehv043.
- Heart U.K. The cholesterol charity: portfolio diet. 2014.
- Viguiiokouk E, Glenn AJ, Nishi SK, Chiavaroli L, Seider M, Khan T, Bonaccio M, Iacoviello L, Mejia SB, Jenkins DJA, et al. Associations between dietary pulses alone or with other legumes and cardiometabolic

- disease outcomes: an umbrella review and updated systematic review and meta-analysis of prospective cohort studies. *Adv Nutr*. 2019;10:S308–S319. DOI: 10.1093/advances/nmz113.
14. Veronese N, Solmi M, Caruso MG, Giannelli G, Osella AR, Evangelou E, Maggi S, Fontana L, Stubbs B, Tzoulaki I. Dietary fiber and health outcomes: an umbrella review of systematic reviews and meta-analyses. *Am J Clin Nutr*. 2018;107:436–444. DOI: 10.1093/ajcn/nqx082.
 15. Mayhew AJ, de Souza RJ, Meyre D, Anand SS, Mente A. A systematic review and meta-analysis of nut consumption and incident risk of cvd and all-cause mortality. *Br J Nutr*. 2016;115:212–225. DOI: 10.1017/S0007114515004316.
 16. Schwingshackl L, Hoffmann G. Monounsaturated fatty acids, olive oil and health status: a systematic review and meta-analysis of cohort studies. *Lipids Health Dis*. 2014;13:154. DOI: 10.1186/1476-511X-13-154.
 17. Zeraatkar D, Han MA, Guyatt GH, Vernooij RWM, El Dib R, Cheung K, Milio K, Zworth M, Bartoszko JJ, Valli C, et al. Red and processed meat consumption and risk for all-cause mortality and cardiometabolic outcomes: a systematic review and meta-analysis of cohort studies. *Ann Intern Med*. 2019;171:703–710. DOI: 10.7326/M19-0655.
 18. Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts. *N Engl J Med*. 2018;378:e34. DOI: 10.1056/NEJMoa1800389.
 19. Prentice RL, Furberg C, Johnson S, Henderson M, Cummings S, Manson J, Freedman L, Oberman A, Kuller L, Anderson G. Design of the whi clinical trial and observational study. *Control Clin Trials*. 1998;19:61–109.
 20. Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allen C, Rossouw JE. The Women's Health Initiative recruitment methods and results. *Ann Epidemiol*. 2003;13:S18–S77. DOI: 10.1016/S1047-2797(03)00042-5.
 21. Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M. The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. *Ann Epidemiol*. 2003;13:S107–S121. DOI: 10.1016/S1047-2797(03)00047-4.
 22. Patterson RE, Kristal AR, Tinker LF, Carter RA, Bolton MP, Agurs-Collins T. Measurement characteristics of the Women's Health Initiative food frequency questionnaire. *Ann Epidemiol*. 1999;9:178–187. DOI: 10.1016/S1047-2797(98)00055-6.
 23. Block G, Hartman AM, Dresser CM, Carroll MD, Gannon J, Gardner L. A data-based approach to diet questionnaire design and testing. *Am J Epidemiol*. 1986;124:453–469. DOI: 10.1093/oxfordjournals.aje.a114416.
 24. Belin RJ, Greenland P, Allison M, Martin L, Shikany JM, Larson J, Tinker L, Howard BV, Lloyd-Jones D, Van Horn L. Diet quality and the risk of cardiovascular disease: the Women's Health Initiative (WHI). *Am J Clin Nutr*. 2011;94:49–57. DOI: 10.3945/ajcn.110.011221.
 25. Curb JDavid, Mctiernan A, Heckbert SR, Kooperberg C, Stanford J, Nevitt M, Johnson KC, Proulx-Burns L, Pastore L, Criqui M, et al. Outcomes ascertainment and adjudication methods in the women's health initiative. *Ann Epidemiol*. 2003;13:S122–128. DOI: 10.1016/S1047-2797(03)00048-6.
 26. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. *Stat Methods Med Res*. 2007;16:219–242. DOI: 10.1177/0962280206074463.
 27. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J*. 2017;38:2459–2472. DOI: 10.1093/eurheartj/ehx144.
 28. Ference BA, Cannon CP, Landmesser U, Luscher TF, Catapano AL, Ray KK. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. *Eur Heart J*. 2018;39:2540–2545. DOI: 10.1093/eurheartj/ehx450.
 29. Ras RT, van der Schouw YT, Trautwein EA, Sioen I, Dalmeijer GW, Zock PL, Beulens JW. Intake of phytosterols from natural sources and risk of cardiovascular disease in the European Prospective Investigation into Cancer and Nutrition-the Netherlands (EPIC-NL) population. *Eur J Prev Cardiol*. 2015;22:1067–1075. DOI: 10.1177/2047487314554864.
 30. Chiavaroli L, Vigiouliouk E, Nishi S, Blanco Mejia S, Rahelić D, Kahleová H, Salas-Salvadó J, Kendall C, Sievenpiper J. Dash dietary pattern and cardiometabolic outcomes: an umbrella review of systematic reviews and meta-analyses. *Nutrients*. 2019;11:338.
 31. Glenn AJ, Vigiouliouk E, Seider M, Boucher BA, Khan TA, Blanco Mejia S, Jenkins DJA, Kahleová H, Rahelić D, Salas-Salvadó J, et al. Relation of vegetarian dietary patterns with major cardiovascular outcomes: a systematic review and meta-analysis of prospective cohort studies. *Front Nutr*. 2019;6:80. DOI: 10.3389/fnut.2019.00080.
 32. Becerra-Tomas N, Blanco Mejia S, Vigiouliouk E, Khan T, Kendall CWC, Kahleová H, Rahelić D, Sievenpiper JL, Salas-Salvado J. Mediterranean diet, cardiovascular disease and mortality in diabetes: a systematic review and meta-analysis of prospective cohort studies and randomized clinical trials. *Crit Rev Food Sci Nutr*. 2020;60:1207–1227. DOI: 10.1080/10408398.2019.1565281.
 33. Lassale C, Gunter MJ, Romaguera D, Peelen LM, Van der Schouw YT, Beulens JWW, Freisling H, Muller DC, Ferrari P, Huybrechts I, et al. Diet quality scores and prediction of all-cause, cardiovascular and cancer mortality in a pan-European cohort study. *PLoS One*. 2016;11:e0159025. DOI: 10.1371/journal.pone.0159025.
 34. George SM, Ballard-Barbash R, Manson JE, Reedy J, Shikany JM, Subar AF, Tinker LF, Vitolins M, Neuhaus ML. Comparing indices of diet quality with chronic disease mortality risk in postmenopausal women in the Women's Health Initiative Observational Study: evidence to inform national dietary guidance. *Am J Epidemiol*. 2014;180:616–625. DOI: 10.1093/aje/kwu173.
 35. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. *Lancet*. 2010;376:112–123. DOI: 10.1016/S0140-6736(10)60834-3.
 36. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke*. 1991;22:983–988. DOI: 10.1161/01.STR.22.8.983.
 37. Sranacharoenpong K, Soret S, Harwatt H, Wien M, Sabate J. The environmental cost of protein food choices. *Public Health Nutr*. 2015;18:2067–2073. DOI: 10.1017/S1368980014002377.
 38. Ritchie H. You want to reduce the carbon footprint of your food? Focus on what you eat, no whether your food is local. 2020.
 39. Fox N, Ward K. Health, ethics and environment: a qualitative study of vegetarian motivations. *Appetite*. 2008;50:422–429. DOI: 10.1016/j.appet.2007.09.007.
 40. Tilman D, Clark M. Global diets link environmental sustainability and human health. *Nature*. 2014;515:518–522. DOI: 10.1038/nature13959.
 41. Vigiouliouk E, Stewart S, Jayalath V, Ng A, Mirrahimi A, de Souza R, Hanley A, Bazinet R, Blanco Mejia S, Leiter L, et al. Effect of replacing animal protein with plant protein on glycemic control in diabetes: a systematic review and meta-analysis of randomized controlled trials. *Nutrients*. 2015;7:9804–9824. DOI: 10.3390/nu7125509.
 42. Mudryj AN, Aukema HM, Yu N. Intake patterns and dietary associations of soya protein consumption in adults and children in the Canadian Community Health Survey, Cycle 2.2. *Br J Nutr*. 2015;113:299–309. DOI: 10.1017/S0007114514003638.
 43. Klingberg S, Andersson H, Mulligan A, Bhaniani A, Welch A, Bingham S, Khaw KT, Andersson S, Ellegard L. Food sources of plant sterols in the EPIC Norfolk population. *Eur J Clin Nutr*. 2008;62:695–703. DOI: 10.1038/sj.ejcn.1602765.
 44. Klingberg S, Ellegard L, Johansson I, Hallmans G, Weinehall L, Andersson H, Winkvist A. Inverse relation between dietary intake of naturally occurring plant sterols and serum cholesterol in northern Sweden. *Am J Clin Nutr*. 2008;87:993–1001. DOI: 10.1093/ajcn/87.4.993.
 45. Jenkins DJA, Kendall CWC, Popovich DG, Vidgen E, Mehling CC, Vuksan V, Ransom TPP, Rao AV, Rosenberg-Zand R, Tariq N, et al. Effect of a very-high-fiber vegetable, fruit, and nut diet on serum lipids and colonic function. *Metabolism*. 2001;50:494–503. DOI: 10.1053/meta.2001.21037.
 46. Guasch-Ferre M, Liu G, Li Y, Sampson L, Manson JE, Salas-Salvado J, Martinez-Gonzalez MA, Stampfer MJ, Willett WC, Sun Q, et al. Olive oil consumption and cardiovascular risk in U.S. adults. *J Am Coll Cardiol*. 2020;75:1729–1739.
 47. Schakel SF, Sievert YA, Buzzard IM. Sources of data for developing and maintaining a nutrient database. *J Am Diet Assoc*. 1988;88:1268–1271.
 48. National Institute for Health and Welfare. Finnish food composition database. 2018.

49. US Department of Agriculture. USDA national nutrient database for standard reference. 2018.
50. Jimenez-Escrig A, Santos-Hidalgo AB, Saura-Calixto F. Common sources and estimated intake of plant sterols in the Spanish diet. *J Agric Food Chem*. 2006;54:3462–3471. DOI: 10.1021/jf053188k.
51. Normén L, Ellegård L, Brants H, Dutta P, Andersson H. A phytosterol database: fatty foods consumed in Sweden and the Netherlands. *J Food Compos Anal*. 2007;20:193–201. DOI: 10.1016/j.jfca.2006.06.002.
52. Normen L, Bryngelsson S, Johnsson M. The phytosterol content of some cereal foods commonly consumed in Sweden and the Netherlands. *J Food Compos Anal*. 2002;15:693–704.
53. Phillips KM, Ruggio DM, Ashraf-Khorassani M. Phytosterol composition of nuts and seeds commonly consumed in the United States. *J Agric Food Chem*. 2005;53:9436–9445. DOI: 10.1021/jf051505h.
54. Irwin ML, McTiernan A, Manson JE, Thomson CA, Sternfeld B, Stefanick ML, Wactawski-Wende J, Craft L, Lane D, Martin LW, et al. Physical activity and survival in postmenopausal women with breast cancer: results from the Women's Health Initiative. *Cancer Prev Res (Phila)*. 2011;4:522–529. DOI: 10.1158/1940-6207.CAPR-10-0295.
55. Heckbert SR, Kooperberg C, Safford MM, Psaty BM, Hsia J, McTiernan A, Gaziano JM, Frishman WH, Curb JD. Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the women's health initiative. *Am J Epidemiol*. 2004;160:1152–1158. DOI: 10.1093/aje/kwh314.
56. Conen D, Ridker PM, Mora S, Buring JE, Glynn RJ. Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. *Eur Heart J*. 2007;28:2937–2943. DOI: 10.1093/eurheartj/ehm400.
57. Margolis KL, Lihong Q, Brzyski R, Bonds DE, Howard BV, Kempainen S, Simin L, Robinson JG, Safford MM, Tinker LT, et al. Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements. *Clin Trials*. 2008;5:240–247. DOI: 10.1177/1740774508091749.

SUPPLEMENTAL MATERIAL

Data S1.

Supplemental Methods

Study design:

At baseline, participants reported information on demographic factors, health behaviors, and medical histories using self-administered questionnaires. At the baseline clinic visit, trained staff measured weight and height.

Dietary Assessment:

Diet was assessed by a 122-item modified Block food frequency questionnaire (FFQ) developed and validated for the WHI population²². The FFQ was administered at baseline for all participants, and again at year 3 for observational study participants. The FFQ asked questions about frequency of food consumption over the previous 3 months, with 19 adjustment items primarily related to fat intake, and 4 summary questions²². The frequency questions included predefined responses that ranged from “never or less than once per month” to “2 or more times per day” for foods and “6 or more times per day” for drinks. Small, medium or large portion sizes were assessed as compared to specified medium size portions. Pictures were provided to help with portion size estimation. The nutrient database for the WHI FFQ uses the Nutrition Data Systems for Research (NDS-R, version 2006), University of Minnesota Nutrition Coordinating Center, Minneapolis, MN) food and nutrient database⁴⁷.

Portfolio Diet Score development:

We previously developed a diet score for assessing adherence to the Portfolio Diet. Food items recommended in the Portfolio Diet were extracted from the WHI FFQ and categorized into the 6 components of the Portfolio Diet (refer to Tables 2 and S1). For most components, servings/day were summed over all consumed food items in each component for every participant. More points were given to participants with higher intakes of foods recommended in the Portfolio Diet, whereas less points were given to participants with higher intakes of foods not recommended in the Portfolio Diet. These points were given for each of the 6 dietary components by splitting the components into quintiles: those in the highest quintile of foods recommended (such as nuts) received 5 points and those in the lowest quintile received 1 point. Reverse scoring was done for those with foods not recommended (such as foods high in saturated fat), as those with the highest intake (quintile 5) received 1 point, and those with the lowest intake (quintile 1) received 5 points. The total points were then added for each participant, resulting in a score range between 6 and 30, with higher scores indicating higher adherence to the Portfolio diet. Food items from the FFQ and included in our Portfolio Diet score are in Table S1.

Plant sterols was the only score component based on mg/day. All other components are food-based in servings/day. The WHI FFQ compositional database did not have plant sterols available as a nutrient variable for their FFQ. Therefore, we developed a plant sterol database (mg/d) based on literature values for ~350 foods and created recipes to match the 122 food items in the WHI FFQ. A number of data sources were used, including European databases: the Finnish Food Composition Database⁴⁸, and the database used in the European Prospective Cohort into Cancer (EPIC) cohort²⁹; the United States Department of Agriculture (USDA)⁴⁹ and other literature^{43,50-53}. We created recipes and determined plant sterol values for foods in the WHI FFQ that did not have a plant sterol values available in the literature, using the ESHA Research Food Processor SQL: Nutrition Analysis and Fitness Program (Copyright 2012, ESHA Research).

Additionally, our approach for determining the Portfolio Diet score was based on several factors. First, we chose population-based intake cut-offs rather than the absolute amounts of the Portfolio Diet components from the clinical trials, as we would not expect a substantial portion of the population to follow the Portfolio Diet, particularly because the FFQ data in WHI were collected before the Portfolio Diet trials were conducted and published. FFQs are also not designed to measure absolute intake, and are better suited for ranking individuals, therefore a population-based cut-off is more appropriate. In addition, we primarily chose a food-based approach rather than a nutrient-based approach as this reflects how the Portfolio Diet is implemented in clinical practice, food-based recommendations may be easier to interpret, and they are more suitable and transferable to multiple FFQs. We did not weight the six components differently as although evidence has shown that a low saturated fat intake may lower LDL-C more than the other components, weighting the components differently did not change the results of preliminary work we had done when developing the Portfolio Diet score. We therefore believe our current method

assesses greater adherence to the Portfolio Diet, while still allowing for adequate variation in the scores to examine associations with disease outcomes in prospective cohorts.

Outcomes:

Heart failure outcome included in the study is the original WHI outcome, referred to as congestive heart failure (CHF). Subtypes based on reduced/preserved ejection fraction rate were not recorded, and therefore not assessed in this analysis. Atrial fibrillation outcomes were collected in WHI extension 2 and beyond and is only adjudicated for the Medical Record Cohort.

Covariates:

Additional information on baseline measurements are included as follows:

Physical activity: Women reported the frequency, duration, and intensity of recreational physical activity, including walking, mild, moderate, and strenuous activity²¹ using a validated physical activity questionnaire. From these data, metabolic equivalents of physical activities in metabolic equivalents-hours/wk (kcal/wk per kg) were computed⁵⁴.

Medical history: In the medical history questionnaire, women were asked (yes/no), “Has a doctor told you that you have, or have you had high cholesterol requiring pills?” for baseline lipid-lowering medication use. Baseline hypertensive status was self-selected as “never hypertensive,” “untreated hypertensive,” or “treated hypertensive.” Subjects were also asked, “Has a doctor ever told you that you had heart problems, problems with your blood circulation, or blood clots?” Previous validation studies have found self-report of CVD at baseline in the WHI to be reliable^{55,56}. For baseline diabetes status, participants were asked if a physician had ever told them they had “sugar diabetes or high blood sugar” when they were not pregnant, and about treatment with insulin or oral diabetes medications. Diabetes was defined as a confirmatory answer to the above question or reported use of medication to treat diabetes. A validation study of the accuracy of self-reported diabetes was found to be reliable⁵⁷.

Body weight: Trained and certified WHI clinical staff measured height and weight using standardized procedures. Weight was measured using a calibrated balance-beam scale and height using a fixed stadiometer. From these measurements, body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared¹⁹.

Statistical Analyses:

Time to event: The time to event was measured as the number of days since enrollment to the first occurrence of a cardiovascular event. Otherwise, participants were censored at the time of a woman’s last documented follow-up contact, whether due to loss of follow-up, non-cardiovascular death or end of study.

Cumulative average: For participants who completed two food frequency questionnaires (FFQs, at baseline and year 3 in the observational study (OS)) the cumulative average of the Portfolio Diet score was related to CVD outcomes. Therefore, if a participant in the OS study had a CVD event before the year 3 FFQ was completed, the baseline Portfolio Diet score was related to the CVD outcomes in our analyses. Otherwise, CVD outcomes were related to the average of the diet scores from both FFQs. The person correlation coefficient between the baseline and year 3 Portfolio Diet scores was 0.63 (<0.05).

Short list of WHI Investigators

Program Office: (National Heart, Lung, and Blood Institute, Bethesda, Maryland) Jacques Rossouw, Shari Ludlam, Joan McGowan, Leslie Ford, and Nancy Geller.

Clinical Coordinating Center: (Fred Hutchinson Cancer Research Center, Seattle, WA) Garnet Anderson, Ross Prentice, Andrea LaCroix, and Charles Kooperberg.

Investigators and Academic Centers:

(Brigham and Women's Hospital, Harvard Medical School, Boston, MA) JoAnn E. Manson; (MedStar Health Research Institute/Howard University, Washington, DC) Barbara V. Howard; (Stanford Prevention Research Center, Stanford, CA) Marcia L. Stefanick; (The Ohio State University, Columbus, OH) Rebecca Jackson; (University of Arizona, Tucson/Phoenix, AZ) Cynthia A. Thomson; (University at Buffalo, Buffalo, NY) Jean Wactawski-Wende; (University of Florida, Gainesville/Jacksonville, FL) Marian Limacher; (University of Iowa, Iowa City/Davenport, IA) Jennifer Robinson; (University of Pittsburgh, Pittsburgh, PA) Lewis Kuller; (Wake Forest University School of Medicine, Winston-Salem, NC) Sally Shumaker; (University of Nevada, Reno, NV) Robert Brunner; (University of Minnesota, Minneapolis, MN) Karen L. Margolis Women's Health Initiative Memory Study; (Wake Forest University School of Medicine, Winston-Salem, NC) Mark Espeland.

For a list of all the investigators who have contributed to WHI science, please visit:

<https://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI%20Investigator%20Long%20List.pdf>

Table S1. Key Characteristics between included and excluded participants.

Mean (SD)/ No. (%)	Included	Excluded*
Number of participants	123,330	5,884
Time-to-event/censored in years	15.3 (5.67)	13.1 (5.97)
Age (years)	62.6 (7.14)	63.4 (7.47)
BMI (kg/m ²)	27.8 (5.83)	27.9 (6.02)
Recreational physical activity (MET-hour/week)	12.8 (13.9)	11.9 (14.7)
Dietary energy (kcal/day)	1642 (640.5)	1252 (1552)
Region in the U.S		
Northeast	28491 (23.1)	1030 (18.4)
South	31376 (25.4)	1912 (34.2)
Midwest	27106(22.0)	1007 (18.0)
West	36357 (29.5)	1650 (29.5)
Race/ethnicity		
White	103284 (84.0)	3649 (65.5)
African American	10118 (8.2)	1061 (19.0)
Hispanic	4875 (4.0)	567 (10.2)
Asian	3390 (1.1)	205 (1.6)
Alcoholic Drinks		
>7 drinks/week	3846 (11.8)	342 (6.5)
Sodium intake (mg/day)	2742 (1152)	2131 (2870)
Hormone therapy use		
Never	40050 (33.5)	2201 (40.0)
Past	26594 (22.2)	1283 (23.3)
Current	52953 (44.3)	2017 (36.4)
Hysterectomy ever	49172 (40.0)	2428 (43.4)
Treated high cholesterol	13466 (11.6)	765 (14.7)
History of hypertension	36629 (30.0)	1731 (32.3)
History of cancer	10512 (8.6)	506 (9.0)
Family history diabetes	38664 (31.5)	1802 (34.0)
Family history of CVD	80129 (65.0)	3256 (55.3)
Self-reported diabetes	5741 (4.7)	394 (7.0)
Smoking status		
Never	63331 (51.4)	2266 (57.3)
Past	51578 (41.8)	1323 (33.5)
Current	8421 (6.8)	365 (9.23)
Education: college or above	83887 (68.5)	3086 (55.9)
Marital status: present relationship	78403 (63.9)	2924 (52.8)
HRT arm		
Not randomized	101653 (82.4)	4528 (80.9)
E-alone	3987 (3.2)	215 (3.8)
E-alone control	4098 (3.3)	247 (4.4)
E+P intervention	6972 (5.7)	305 (5.5)
E+P control	6620 (5.4)	304 (5.3)
DM arm		
Not randomized	84243 (68.3)	4990 (89.1)
Intervention	15588 (12.6)	251 (4.5)
Control	23499 (19.1)	358 (6.7)
CaD arm		
Not randomized	93911 (75.2)	4822 (86.1)
Intervention	14774 (12.0)	406 (7.25)
Control	14645 (11.9)	371 (6.63)

BMI, body mass index; CaD, calcium and vitamin D; CVD, cardiovascular disease; DM, dietary modification; E-alone, estrogen-alone; E+P, estrogen plus progestin;

HRT, hormone replacement therapy; Kcal, kilocalories; MET, metabolic equivalents; Q, quartile; SD, standard deviation; U.S., United States.

*A combination of 3,540 participants who had implausible energy intake and 2,344 who had missing covariates for model 1 (only smoking data was missing in this case) and missing time to event data.

Table S2. Full line items from WHI FFQ used to calculate the Portfolio Diet score primarily based on servings/day.

Component	
Plant protein	(1) Soy milk as beverage; (2) green or English peas; (3) refried beans, (4) all other beans such as baked beans, lima beans, black-eyed peas and chili without meat; (5) tofu and textured vegetable products; (6) bean soups such as pea, lentil, black bean, potajes
Viscous fiber	(1) Oranges, grapefruit & tangerines; (2) apples & pears; (3) strawberries & kiwi*; (4) summer squash, zucchini, nopales & okra [†] ; (5) cooked cereals & grits [‡]
Nuts	(1) Peanut butter, peanuts, other nuts and seeds
Plant sterols	Estimated from all foods on FFQ (mg/day)
MUFAs	(1) Olive or canola oil as spread or added to food; (2) avocado & guacamole, including added to mixed dishes
Saturated fat	(1) Whole milk as beverage; (2) ground meat including hamburgers, meatloaf & picadillo; (3) beef, pork and lamb as a main dish, such as steak, roast and ham; (4) beef, pork and lamb as a sandwich (steak sandwich, BBQ sandwich); (5) Liver, including chicken liver and other organs; (6) Gravies made with meat drippings; (7) Lunch meat such as ham, turkey and other special lean meats; (8) All other lunch meat such as bologna, salami, Spam®, potted and canned meat; (9) Hot dogs, chorizo, and other sausage such as bratwurst; (10) eggs; (11) bacon, breakfast sausage and scrapple; (12) all other cheeses, such as cheddar, Swiss, or cream cheese; (13) ice cream; (14) fried chicken; (15) chicken or turkey (with skin only); (16) butter as spread, or added to food or cereal

*Half of question amount assumed to be strawberries; [†]One quarter of question amount assumed to be okra; [‡]Half of cooked cereal question amount assumed to be oats.

Table S3. Sensitivity analyses of the association of the Portfolio Diet score based on RCT recommendations and cardiovascular outcomes.

		TOTAL CVD		CHD		STROKE		HEART FAILURE		ATRIAL FIBRILLATION	
		HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Portfolio diet score (0-7 points)		0.96 (0.94-0.99)	<0.01	0.96 (0.93-1.00)	0.05	0.94 (0.90-0.99)	0.01	0.91 (0.86-0.97)	<0.01	1.02 (0.93-1.13)	0.61
Portfolio diet Score tertiles*	N										
Q1 (0-2 points) 0-14% adherent	60,097	1.00 [reference]		1.00 [reference]		1.00 [reference]		1.00 [reference]		1.00 [reference]	
Q2 (3 points) 22% adherent	61,094	0.94 (0.90-0.99)	0.01	0.95 (0.89-1.02)	0.17	0.91 (0.84-0.99)	0.02	0.90 (0.80-1.01)	0.07	0.99 (0.84-1.18)	0.98
Q3 (4-7 points) 29-50% adherent	4,198	0.90 (0.80-1.00)	0.05	0.87 (0.74-1.05)	0.18	0.94 (0.78-1.13)	0.52	0.79 (0.57-1.08)	0.14	1.13 (0.75-1.71)	0.56

CHD, coronary heart disease; CVD, cardiovascular disease; HR, hazard ratio.

*Tertiles used instead of quartiles as per previous analysis based on range of 0-7 points (original analysis was 6-30).

The hazard ratios (HRs) are for assessing the Portfolio Diet score as a continuous exposure (0-7 points) and for comparing participants in Q1 (low adherence) to Q3 (high adherence) to the Portfolio Diet components based on recommendations from the Portfolio Diet RCTs (50g plant protein, 45g nuts, 20g viscous fiber, 2g plant sterols, 45g MUFAs, <7% energy from saturated fat and <200mg cholesterol per day). The scoring system to assess adherence to the Portfolio Diet score was based on 0-14 points (2 points for meeting previously listed 7 targets, 1 point for meeting half, and 0 points for less than half). Maximum score obtained was 7 points, therefore, 50% maximum adherence to the Portfolio Diet recommendations from the RCTs, with an average 22% adherence. Adherence to plant protein, viscous fiber and MUFAs was based on estimations of grams/servings for most commonly consumed foods in this category (plant protein was lentils/beans & green peas, viscous fiber was apples & oranges, and MUFAs were avocados). The remaining components were based on grams/day from the entire day as estimated from the FFQ.

The Cox regression models were adjusted for age, ethnicity, education, marital status, hysterectomy history, BMI, physical activity, smoking, alcohol intake, region in the U.S, study arm, energy intake, cancer status, hypertension status, diabetes status, sodium intake, family history of CVD, family history of diabetes, hormone therapy use, cholesterol lowering medication use. Under/over energy reporters and those with baseline CVD were excluded from the analysis.

Table S4. Sensitivity analyses of the association of the Portfolio Diet score and cardiovascular outcomes.

	Baseline Portfolio Diet Score only		Without Dietary Modification Participants		Removing those diagnosed in first 3 years		Excluding those with diabetes diagnosis		Multiple imputation of missing covariates	
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
TOTAL CVD										
Cases/total n	13,365/ 104,894		8,990/ 73,442		11,240/ 103,098		11,962/ 100,149		13,558/ 125,389	
Portfolio Score by Quartiles										
Q1	1.00 [reference]		1.00 [reference]		1.00 [reference]		1.00 [reference]		1.00 [reference]	
Q2	0.98 (0.93-1.03)	0.38	0.95 (0.89-1.01)	0.10	0.98 (0.92-1.03)	0.38	0.97 (0.92-1.02)	0.23	0.95 (0.91-0.99)	0.025
Q3	0.94 (0.87-0.97)	0.035	0.86 (0.81-0.92)	<0.001	0.92 (0.87-0.98)	0.006	0.91 (0.86-0.96)	0.001	0.89 (0.85-0.94)	<0.001
Q4	0.89 (0.84-0.95)	0.001	0.86 (0.80-0.93)	<0.001	0.88 (0.82-0.94)	<0.001	0.88 (0.82-0.94)	<0.001	0.86 (0.81-0.91)	<0.001
<i>P</i> trend		<0.001		<0.001		<0.001		<0.001		<0.001
CHD										
Cases/total n	5,640/ 104,894		3,810/ 72,442		4,924/ 104,302		5,006/ 100,152		5,739/ 125,389	
Portfolio Score by Quartiles										
Q1 (6-14)	1.00 [reference]		1.00 [reference]		1.00 [reference]		1.00 [reference]		1.00 [reference]	
Q2 (14.5-17)	0.96 (0.89-1.04)	0.29	0.91 (0.82-0.99)	0.04	0.92 (0.84-1.00)	0.05	0.90 (0.83-0.98)	0.01	0.89 (0.82-0.95)	0.001
Q3 (17.5-20)	0.89 (0.92-0.97)	<0.009	0.82 (0.74-0.91)	<0.001	0.85 (0.78-0.93)	<0.001	0.84 (0.77-0.92)	<0.001	0.84 (0.78-0.91)	<0.001
Q4 (20.5-30)	0.91 (0.83-0.99)	0.048	0.85 (0.76-0.95)	0.005	0.86 (0.78-0.96)	0.005	0.85 (0.77-0.94)	0.002	0.83 (0.76-0.91)	<0.002
<i>P</i> trend		<0.001		0.001		0.001		0.001		<0.001
STROKE										
Cases/total n	4,440/ 104,894		2,960/ 73,441		3,807/ 104,390		4,039/ 100,151		4,451/ 125,892	
Portfolio Score by Quartiles										
Q1 (6-14)	1.00 [reference]		1.00 [reference]		1.00 [reference]		1.00 [reference]		1.00 [reference]	
Q2 (14.5-17)	1.05 (0.96-1.15)	0.29	0.99 (0.89-1.10)	0.83	1.03 (0.93-1.14)	0.56	1.06 (0.96-1.16)		1.02 (0.95-1.11)	0.55

Q3 (17.5-20)	0.99 (0.90-1.09)	0.88	0.88 (0.78-0.99)	0.04	0.99 (0.89-1.10)	0.81	0.98 (0.89-1.09)		0.95 (0.88-1.03)	0.23
Q4 (20.5-30)	0.97 (0.87-1.08)	0.54	0.90 (0.79-1.03)	0.11	0.97 (0.86-1.09)	0.64	0.99 (0.88-1.10)		0.94 (0.85-1.04)	0.22
<i>P</i> trend		0.50		0.06		0.55		0.63		0.13
HEART FAILURE										
Cases/total n	1,907/ 104,894		1,303/ 73,440		1,467/ 104,519		1,557/ 100,150		1,946/ 125,389	
Portfolio Score by Quartiles										
Q1 (6-14)	1.00 [reference]		1.00 [reference]		1.00 [reference]		1.00 [reference]		1.00 [reference]	
Q2 (14.5-17)	0.94 (0.82-1.07)	0.34	0.94 (0.80-1.10)	0.42	0.96 (0.83-1.12)	0.64	0.92 (0.80-1.07)	0.29	0.98 (0.87-1.11)	0.79
Q3 (17.5-20)	0.92 (0.80-1.06)	0.26	0.79 (0.66-0.94)	0.008	0.86 (0.73-1.02)	0.09	0.86 (0.73-1.01)	0.07	0.88 (0.77-1.01)	0.06
Q4 (20.5-30)	0.79 (0.66-0.92)	0.005	0.81 (0.66-0.99)	0.035	0.85 (0.70-1.03)	0.10	0.86 (0.72-1.04)	0.11	0.79 (0.68-0.92)	0.002
<i>P</i> trend		0.010		0.005		0.05		0.05		0.001
ATRIAL FIBRILLATION*										
Cases/total n	929/ 104,894		634/ 73,442		0/ 104,894		874/ 100,152		935/ 125,389	
Portfolio Score by Quartiles										
Q1 (6-14)	1.00 [reference]		1.00 [reference]		NA	NA	1.00 [reference]		1.00 [reference]	
Q2 (14.5-17)	1.06 (0.87-1.27)	0.61	1.16 (0.92-1.47)	0.20	NA	NA	1.05 (0.86-1.29)	0.61	1.04 (0.87-1.23)	0.69
Q3 (17.5-20)	0.95 (0.77-1.17)	0.62	0.97 (0.75-1.25)	0.79	NA	NA	0.97 (0.78-1.20)	0.76	0.94 (0.77-1.14)	0.51
Q4 (20.5-30)	1.09 (0.86-1.40)	0.47	1.08 (0.82-1.43)	0.57	NA	NA	1.12 (0.88-1.42)	0.34	1.08 (0.88-1.34)	0.45
<i>P</i> trend		0.73		0.88	NA	NA		0.56		0.75

CHD, coronary heart disease; CVD, cardiovascular disease; HR, hazard ratio; NA, not applicable as analyses could not be conducted.

Cox regression model adjusted for age, ethnicity, education, marital status, hysterectomy history, BMI, physical activity, smoking, alcohol intake, region in the U.S, study arm, energy intake, cancer status, hypertension status, diabetes status, sodium intake, family history of CVD, family history of diabetes, hormone therapy use, cholesterol lowering medication use. Under/over energy reporters and those with baseline CVD were excluded from the analysis. *No atrial fibrillation cases diagnosed in the first 3 years

Table S5. Associations between high to low adherence to the individual components of the Portfolio diet and risk of cardiovascular outcomes.

Portfolio Diet Component	Total CVD	CHD	Stroke	Heart Failure	Atrial fibrillation
	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)
Plant protein sources	0.99 (0.93-1.06)	1.00 (0.91-1.11)	1.03 (0.92-1.15)	1.03 (0.87-1.22)	1.02 (0.80-1.30)
<i>P</i> value	0.89	0.90	0.59	0.74	0.88
Nuts	0.90 (0.84-0.95)	0.92 (0.83-1.01)	0.94 (0.84-1.05)	0.78 (0.66-0.92)	0.98 (0.76-1.25)
<i>P</i> value	0.001	0.07	0.29	0.004	0.86
Viscous fiber sources	0.95 (0.89-1.01)	0.92 (0.84-1.01)	1.01 (0.91-1.13)	0.90 (0.77-1.07)	1.00 (0.80-1.26)
<i>P</i> value	0.09	0.08	0.82	0.23	0.99
Plant sterols	0.90 (0.82-0.98)	0.83 (0.73-0.95)	0.84 (0.72-0.98)	0.87 (0.69-1.10)	1.02 (0.73-1.42)
<i>P</i> value	0.02	0.006	0.03	0.24	0.90
MUFA sources	0.92 (0.87-0.97)	0.93 (0.85-1.01)	0.95 (0.86-1.05)	0.90 (0.77-1.04)	1.04 (0.84-1.29)
<i>P</i> value	0.003	0.09	0.30	0.16	0.71
Low saturated fat sources*	0.89 (0.83-0.96)	0.90 (0.80-0.99)	0.95 (0.84-1.07)	0.87 (0.72-1.05)	0.99 (0.76-1.30)
<i>P</i> value	0.002	0.04	0.41	0.14	0.95

CHD, coronary heart disease; CVD, cardiovascular disease; HR, hazard ratio.


The hazard ratios (HRs) are for comparing participants in Q1 (low adherence) to Q5 (high adherence) to the Portfolio Diet components at baseline and year 3 (cumulative average).

The Cox regression model was adjusted for age, ethnicity, education, marital status, hysterectomy history, BMI, physical activity, smoking, alcohol intake, region in the U.S, study arm, energy intake, cancer status, hypertension status, diabetes status, sodium intake, family history of CVD, family history of diabetes, hormone therapy use, cholesterol lowering medication use.

Under/over energy reporters and those with baseline CVD were excluded from the analysis.

*Saturated fat source quintiles were reversed (i.e. Q5 is lowest adherence, Q1 is highest adherence).


Figure S1. Subgroup analyses of the association between low adherence (Q1) to high adherence (Q4) of the Portfolio Diet score and total CVD.



BMI, body mass index; CVD, cardiovascular disease; HR, hazard ratio

The hazard ratios are for comparing participants in Q1 (low adherence) to Q4 (high adherence) to the Portfolio Diet score. The Cox regression model was adjusted for age, ethnicity, education, marital status, hysterectomy history, BMI, physical activity, smoking, alcohol intake, region in the U.S, study arm, energy intake, cancer status, hypertension status, diabetes status, sodium intake, family history of CVD, family history of diabetes, hormone therapy use, and cholesterol lowering medication use. *P* for interaction is comparing participants in Q1 (low adherence) to Q4 (high adherence) to the Portfolio Diet score. Under/over energy reporters and those with baseline CVD were excluded from the analysis.


Figure S2. Subgroup analyses of the association between low adherence (Q1) to high adherence (Q4) of the Portfolio Diet score and CHD.



BMI, body mass index; CHD, coronary heart diseases; CVD, cardiovascular disease; HR, hazard ratio

The hazard ratios are for comparing participants in Q1 (low adherence) to Q4 (high adherence) to the Portfolio Diet score. The Cox regression model was adjusted for age, ethnicity, education, marital status, hysterectomy history, BMI, physical activity, smoking, alcohol intake, region in the U.S, study arm, energy intake, cancer status, hypertension status, diabetes status, sodium intake, family history of CVD, family history of diabetes, hormone therapy use, and cholesterol lowering medication use. *P* for interaction is comparing participants in Q1 (low adherence) to Q4 (high adherence) to the Portfolio Diet score. Under/over energy reporters and those with baseline CVD were excluded from the analysis


Figure S3. Subgroup analyses of the association between low adherence (Q1) to high adherence (Q4) of the Portfolio Diet score and Stroke.



BMI, body mass index; CVD, cardiovascular disease; HR, hazard ratio

The hazard ratios are for comparing participants in Q1 (low adherence) to Q4 (high adherence) to the Portfolio Diet score. The Cox regression model was adjusted for age, ethnicity, education, marital status, hysterectomy history, BMI, physical activity, smoking, alcohol intake, region in the U.S, study arm, energy intake, cancer status, hypertension status, diabetes status, sodium intake, family history of CVD, family history of diabetes, hormone therapy use, and cholesterol lowering medication use. *P* for interaction is comparing participants in Q1 (low adherence) to Q4 (high adherence) to the Portfolio Diet score. Under/over energy reporters and those with baseline CVD were excluded from the analysis.


Figure S4. Subgroup analyses of the association between low adherence (Q1) to high adherence (Q4) of the Portfolio Diet score and Heart Failure.



BMI, body mass index; CVD, cardiovascular disease; HR, hazard ratio

The hazard ratios are for comparing participants in Q1 (low adherence) to Q4 (high adherence) to the Portfolio Diet score. The Cox regression model was adjusted for age, ethnicity, education, marital status, hysterectomy history, BMI, physical activity, smoking, alcohol intake, region in the U.S, study arm, energy intake, cancer status, hypertension status, diabetes status, sodium intake, family history of CVD, family history of diabetes, hormone therapy use, and cholesterol lowering medication use. *P* for interaction is comparing participants in Q1 (low adherence) to Q4 (high adherence) to the Portfolio Diet score. Under/over energy reporters and those with baseline CVD were excluded from the analysis.

Figure S5. Subgroup analyses of the association between low adherence (Q1) to high adherence (Q4) of the Portfolio Diet score and Atrial Fibrillation.



BMI, body mass index; CVD, cardiovascular disease; HR, hazard ratio; NA, not applicable (too few cases in subgroup).

The hazard ratios are for comparing participants in Q1 (low adherence) to Q4 (high adherence) to the Portfolio Diet score. The Cox regression model was adjusted for age, ethnicity, education, marital status, hysterectomy history, BMI, physical activity, smoking, alcohol intake, region in the U.S., study arm, energy intake, cancer status, hypertension status, diabetes status, sodium intake, family history of CVD, family history of diabetes, hormone therapy use, and cholesterol lowering medication use. *P* for interaction is comparing participants in Q1 (low adherence) to Q4 (high adherence) to the Portfolio Diet score. Under/over energy reporters and those with baseline CVD were excluded from the analysis.